MFG
DFTX

Merit Financial Group’s Definium Therapeutics DFTX Stock Holding History

Merit Financial Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-540,287
Closed -$1.19M – 687
2022
Q4 		$1.19M Sell
540,287
-540,287
-50% -$1.5M 0.04% 263
2022
Q3 		$3.78M Buy
1,080,574
+1,045,082
+2,945% +$10M 0.16% 81
2022
Q2 		$341K Buy
+35,492
New +$449K 0.01% 422

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Merit Financial Group's DFTX Position: Q1 2023 in Review

Merit Financial Group sold out of Definium Therapeutics (DFTX) in Q1 2023, closing a stake of 540,287 shares — an estimated $1.19M sold.

Merit Financial Group first reported a position in DFTX in Q2 2022 and held it in 3 quarters. The position peaked at $3.78M in Q3 2022. 88 funds tracked by Wall St. Rank hold DFTX as of Q1 2023.

  • Merit Financial Group reported no remaining Definium Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Merit Financial Group sold 540,287 Definium Therapeutics shares in Q1 2023, an estimated $1.19M.
  • Merit Financial Group first reported a position in Definium Therapeutics in Q2 2022 and held it in 3 quarters.
  • Merit Financial Group's Definium Therapeutics position peaked at $3.78M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.